It looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
Gene synthesis from €0.14/bp · Sanger-verified
Order custom gene synthesis online: enter your DNA sequence, select your cloning options and get an instant quote.
No Gene, No Fee
Configure & Get Instant Price → Request a Quote →
Have specific requirements or prefer direct contact? Our team can help.
5 days
To obtain your gene
150+
Vector options
AI-powered
Codon optimization
Sanger
Sequence accuracy guaranteed
Use our online ordering platform to submit your DNA sequence and configure your project in just a few steps.
Complete the form below to obtain an instant gene synthesis price estimate and start your project.
GENE SYNTHESIS PRICING
Gene synthesis starts at €0.14/bp, with cloning options available to match your project requirements.
FROM SEQUENCE TO VERIFIED GENE
A connected three-step process from sequence preparation to synthesis, cloning and verification.
STEP 01
Prepare your sequence for synthesis, with optional codon optimization tailored to your selected expression host.
STEP 02
Gene synthesis and assembly, with options for tags, signal peptides, mutations, truncations and domain swaps.
STEP 03
Cloning into the selected vector, followed by Sanger sequence verification and quality-control documentation.
GENE SYNTHESIS DELIVERABLES
Your order includes the synthesized gene, sequence verification and quality-control documentation. Final specifications depend on your selected options.
01
For a standard research-grade cloned gene, the default quantity is 4 µg. Quantity and preparation grade can be customized.
02
Your gene is checked by Sanger sequencing before delivery.
03
Quality-control documentation accompanies the gene synthesis service.
AI-BASED SEQUENCE OPTIMIZATION
Need to adapt your gene for a specific expression host? Run sequence analysis and review the optimized result immediately, without leaving the ordering workflow.
Support expression in your chosen host Adapt codon usage to the target expression system.
CLONING OPTIONS
Choose from 150+ vector options across multiple expression systems to match your gene synthesis project requirements.
When automated platforms reach their limits, our gene synthesis platform steps in. We routinely synthesize and deliver complex constructs.
Working with a difficult DNA sequence? Discuss your sequence characteristics with our scientists to assess feasibility.
EXPERIMENTAL EVIDENCE
Two examples of complex DNA constructs successfully delivered by ProteoGenix, supported by project-specific experimental data.
CASE STUDY 01 · HIGH-GC GENE
2.4 kb gene · Localized regions above 85% GC
GC content profile provided with the project documentation.
PROJECT CHALLENGE
Dense hairpins and G-quadruplexes interfering with standard automated assembly.
REPORTED RESULT
Sanger-verified sequence accuracy with no frameshifts, delivered in a stable plasmid vector.
CASE STUDY 02 · POLY-A CONSTRUCT
Two poly-A segments separated by a 10 bp interruption
Forward and reverse Sanger sequencing traces supplied for the construct.
PROJECT CHALLENGE
Polymerase slippage, recombination-mediated deletions and Sanger trace collapse.
REPORTED RESULT
Delivered without sequence truncation using specialized host strains and custom assembly protocols.
WHY PROTEOGENIX
The right DNA construct starts with the right experimental strategy. At ProteoGenix, we consider how your gene will be used to help guide decisions on sequence optimization, vector selection and cloning.
Protein expression, functional studies and cell line development can call for different construct requirements. Our scientific team helps you evaluate the options before synthesis begins.
The optimized genes ordered were of excellent quality, were cost-effective and perfectly adapted for biochemical and biophysical studies. In addition, the account manager in charge of the service advised us really well before and after the sales process, and we got the constructs on time.
ProteoGenix gene synthesis services cited in recent publications across leading journals.
Moss BRCA2 lacking the canonical DNA-binding domain promotes homologous recombination and binds to DNA.
Alice Chanteau, Suliane Quilleré, Arthur Crouset, Sreejith Allipra, Ulysse Tuquoi, Pierre-François Perroud, Simona Miron, Pauline Dupaigne, Sophie Zinn-Justin, Fabien Nogué, Rajeev Kumar. Nucleic Acids Research. 2025;53(17):gkaf856.
First evidence of efficacy of peptides targeting the pUL56-pUL89 interaction domain of the human cytomegalovirus terminase complex.
Sarah Mafi, Jean-Luc Poyet, Sophie Alain, Gaëtan Ligat, Sébastien Hantz. Antiviral Research. 2025;242:106259.
An Engineered SARS-CoV-2 S1 Glycoprotein Produced in Pichia pastoris as a Candidate Vaccine Antigen.
Sanaz Majidi, Khosrow Aghaiypour Kolyani, Meisam Akrami, Maryam Dadar. Molecular Biotechnology, published in 2025, vol 68 in 2026.
Cecropin anisaxin-2S has in vitro immunomodulatory, but not antiproliferative and antiviral properties.
Jovana Majstorović, Anush Arakelyan, Željka Trumbić, Jan Kamiš, Mikolaj Adamek, Tomislav Rončević, et al. Frontiers in Immunology. 2025;16:1567505.
LET’S DISCUSS YOUR PROJECT
Have specific requirements or prefer to discuss your project directly? Send us your details and our team will help you find the right solution.
Already have your project details?
Share your sequence or requirements directly with our team to request a quote.